Skip to search formSkip to main contentSkip to account menu

S 18327

Known as: 1-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl)ethyl)-3-phenylimidazolin-2-one, S-18327, S18327 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Adrenergic alpha-1 Receptor AntagonistsImidazolesIsoxazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
Generalization of clozapine as compared to other antipsychotic agents to a discriminative stimulus elicited by the serotonin (5-HT)2A antagonist, MDL100,907
2001
2001
Pharmacokinetic‐pharmacodynamic modelling in the early development phase of anti‐psychotics: a comparison of the effects of clozapine, S 16924 and S 18327 in the EEG model in rats
The use of pharmacokinetic/pharmacodynamic (PK/PD) analysis in early compound development was investigated in the rat for two… 
2000
2000
S18327 (1-{2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a Novel, Potential Antipsychotic Displaying Marked Antagonist Properties at α1- and α2-Adrenergic…
S18327 was dose-dependently active in several models of potential antipsychotic activity involving dopaminergic hyperactivity… 
2000
2000
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2…
S18327 displayed modest affinity for human (h)D(2) and hD(3) receptors and high affinity for hD(4) receptors. At each, S18327… 
2000
2000
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2…
S18327 was dose-dependently active in several models of potential antipsychotic activity involving dopaminergic hyperactivity… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License